Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition
DM Wilcock, A Rojiani, A Rosenthal… - Journal of …, 2004 - Soc Neuroscience
The role of microglia in the removal of amyloid deposits after systemically administered anti-
Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic …
Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic …
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-β immunotherapy
A Wang, P Das, RC Switzer, TE Golde… - Journal of …, 2011 - Soc Neuroscience
Many new therapeutics for Alzheimer's disease delay the accumulation of amyloid-β (Aβ) in
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …
Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration
DM Wilcock, SK Munireddy, A Rosenthal, KE Ugen… - Neurobiology of …, 2004 - Elsevier
The mechanisms by which anti-Aβ antibodies clear amyloid plaques in Aβ depositing
transgenic mice are unclear. In the current study, we demonstrate that inhibition of anti-Aβ …
transgenic mice are unclear. In the current study, we demonstrate that inhibition of anti-Aβ …
Intracranially administered anti-Αβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation
DM Wilcock, G DiCarlo, D Henderson… - Journal of …, 2003 - Soc Neuroscience
Active immunization against the β-amyloid peptide (Αβ) with vaccines or passive
immunization with systemic monoclonal anti-Aβ antibodies reduces amyloid deposition and …
immunization with systemic monoclonal anti-Aβ antibodies reduces amyloid deposition and …
Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy
BJ Bacskai, ST Kajdasz, ME McLellan… - Journal of …, 2002 - Soc Neuroscience
Transgenic (Tg) mouse models overexpressing amyloid precursor protein (APP) develop
senile plaques similar to those found in Alzheimer's disease in an age-dependent manner …
senile plaques similar to those found in Alzheimer's disease in an age-dependent manner …
Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/-knock-out mice
P Das, V Howard, N Loosbrock, D Dickson… - Journal of …, 2003 - Soc Neuroscience
Direct immunization with amyloidβ protein (Aβ) and passive transfer of anti-Aβ antibodies
reduce Aβ accumulation and attenuate cognitive deficits in transgenic models of Alzheimer's …
reduce Aβ accumulation and attenuate cognitive deficits in transgenic models of Alzheimer's …
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ
O Adolfsson, M Pihlgren, N Toni, Y Varisco… - Journal of …, 2012 - Soc Neuroscience
Passive immunization against β-amyloid (Aβ) has become an increasingly desirable
strategy as a therapeutic treatment for Alzheimer's disease (AD). However, traditional …
strategy as a therapeutic treatment for Alzheimer's disease (AD). However, traditional …
Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular …
DM Wilcock, A Rojiani, A Rosenthal… - Journal of …, 2004 - Springer
Background Anti-Aβ immunotherapy in transgenic mice reduces both diffuse and compact
amyloid deposits, improves memory function and clears early-stage phospho-tau …
amyloid deposits, improves memory function and clears early-stage phospho-tau …
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
C Wiessner, KH Wiederhold, AC Tissot… - Journal of …, 2011 - Soc Neuroscience
Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is
considered a potential therapeutic approach for Alzheimer's disease. However, it has been …
considered a potential therapeutic approach for Alzheimer's disease. However, it has been …
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard, C Cannon, R Barbour, RL Burke, D Games… - Nature medicine, 2000 - nature.com
One hallmark of Alzheimer disease is the accumulation of amyloid β-peptide in the brain and
its deposition as plaques. Mice transgenic for an amyloid β precursor protein (APP) mini …
its deposition as plaques. Mice transgenic for an amyloid β precursor protein (APP) mini …